Literature DB >> 31900863

Alzheimer's Disease and Diabetes: Insulin Signaling as the Bridge Linking Two Pathologies.

Jonathan Chang-Cheng Shieh1, Pai-Tsang Huang2, Yung-Feng Lin3,4.   

Abstract

Alzheimer's (or Alzheimer) disease (AD) is the most prevalent subset of dementia, affecting elderly populations worldwide. The cumulative costs of the AD care are rapidly accelerating as the average lifespan increases. Onset and risk factors for AD and AD-like dementias have been largely unknown until recently. Studies show that chronic type II diabetes mellitus (DM) is closely associated with neurodegeneration, especially AD. Type II DM is characterized by the cells' inability to take up insulin, as well as chronic hyperglycemia. In the central nervous system, insulin has crucial regulatory roles, while chronic hyperglycemia leads to formation and accumulation of advanced glycation end products (AGEs). AGEs are the major contributor to insulin resistance in diabetic cells, due to their regulatory role on sirtuin expression. Insulin activity in the central nervous system is known to interact with key proteins affected in neurodegenerative conditions, such as amyloid-β precursor protein (AβPP or APP), huntingtin-associated protein-1 (HAP1), Abelson helper integration site-1 (AHI1 or Jouberin), kinesin, and tau. Sirtuins have been theorized to be the mechanism for insulin resistance, and have been found to be affected in neurodegenerative conditions as well. There are hints that all these neuronal proteins may be closely related, although the mechanisms remain unclear. This review will gather existing research on these proteins and highlight the link between neurodegenerative conditions and diabetes mellitus.

Entities:  

Keywords:  Abelson helper integration site-1 (AHI1 or Jouberin); Advanced glycation end products (AGEs); Alzheimer’s (Alzheimer) disease (AD); Amyloid-β precursor protein (AβPP or APP); Diabetes mellitus (DM); Huntingtin-associated protein-1 (HAP1); Insulin resistance; Kinesin

Year:  2020        PMID: 31900863     DOI: 10.1007/s12035-019-01858-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  82 in total

1.  Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.

Authors:  Gorazd B Stokin; Concepción Lillo; Tomás L Falzone; Richard G Brusch; Edward Rockenstein; Stephanie L Mount; Rema Raman; Peter Davies; Eliezer Masliah; David S Williams; Lawrence S B Goldstein
Journal:  Science       Date:  2005-02-25       Impact factor: 47.728

2.  Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain.

Authors:  Chia-Chen Liu; Jin Hu; Chih-Wei Tsai; Mei Yue; Heather L Melrose; Takahisa Kanekiyo; Guojun Bu
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

3.  Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor.

Authors:  Ling Xie; Erik Helmerhorst; Kevin Taddei; Brian Plewright; Wilhelm Van Bronswijk; Ralph Martins
Journal:  J Neurosci       Date:  2002-05-10       Impact factor: 6.167

Review 4.  Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy.

Authors:  D A Greene; M J Stevens; I Obrosova; E L Feldman
Journal:  Eur J Pharmacol       Date:  1999-06-30       Impact factor: 4.432

5.  Elevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141-147 in Taiwanese with Alzheimer's disease.

Authors:  Ching-Yu Lin; Jau-Jiuan Sheu; I-Shih Tsai; Sen-Te Wang; Li-Yu Yang; I-Uen Hsu; Hui-Wen Chang; Horng-Mo Lee; Shu-Huei Kao; Ching-Kuo Lee; Chien-Ho Chen; Yung-Feng Lin
Journal:  Clin Biochem       Date:  2018-04-20       Impact factor: 3.281

Review 6.  Evidence for altered insulin receptor signaling in Alzheimer's disease.

Authors:  Chelsea M Griffith; Tore Eid; Gregory M Rose; Peter R Patrylo
Journal:  Neuropharmacology       Date:  2018-01-17       Impact factor: 5.250

7.  Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation.

Authors:  R J Mark; Z Pang; J W Geddes; K Uchida; M P Mattson
Journal:  J Neurosci       Date:  1997-02-01       Impact factor: 6.167

8.  A huntingtin-associated protein enriched in brain with implications for pathology.

Authors:  X J Li; S H Li; A H Sharp; F C Nucifora; G Schilling; A Lanahan; P Worley; S H Snyder; C A Ross
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

9.  Huntingtin-associated protein 1 interacts with Ahi1 to regulate cerebellar and brainstem development in mice.

Authors:  Guoqing Sheng; Xingshun Xu; Yung-Feng Lin; Chuan-En Wang; Juan Rong; Dongmei Cheng; Junmin Peng; Xiaoyan Jiang; Shi-Hua Li; Xiao-Jiang Li
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

Review 10.  Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models.

Authors:  Nobuyuki Kimura
Journal:  Int J Mol Sci       Date:  2016-04-05       Impact factor: 5.923

View more
  20 in total

1.  Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus.

Authors:  Helena Kullenberg; Jenny Rossen; Unn-Britt Johansson; Maria Hagströmer; Thomas Nyström; Maria Kumlin; Marie M Svedberg
Journal:  Endocrine       Date:  2022-06-25       Impact factor: 3.925

Review 2.  Saffron as a promising therapy for diabetes and Alzheimer's disease: mechanistic insights.

Authors:  Sarvin Sanaie; Saba Nikanfar; Zahra Yousefi Kalekhane; Akbar Azizi-Zeinalhajlou; Saeed Sadigh-Eteghad; Mostafa Araj-Khodaei; Mohammad Hossein Ayati; Sasan Andalib
Journal:  Metab Brain Dis       Date:  2022-08-20       Impact factor: 3.655

Review 3.  Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role.

Authors:  Richa Tyagi; Bhupesh Vaidya; Shyam Sunder Sharma
Journal:  Pharmacol Rep       Date:  2022-09-23       Impact factor: 3.919

4.  Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3×Tg-AD mice.

Authors:  Fei Yan; Ju Liu; Mei-Xiang Chen; Ying Zhang; Sheng-Jiao Wei; Hai Jin; Jing Nie; Xiao-Long Fu; Jing-Shan Shi; Shao-Yu Zhou; Feng Jin
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

5.  A Genetic Model of Epilepsy with a Partial Alzheimer's Disease-Like Phenotype and Central Insulin Resistance.

Authors:  Suélen Santos Alves; Rui Milton Patrício da Silva Junior; Polianna Delfino-Pereira; Marilia Gabriella Alves Goulart Pereira; Israel Vasconcelos; Hanna Schwaemmle; Rodrigo Focosi Mazzei; Maiko Luiz Carlos; Enilza Maria Espreafico; Antônio Claudio Tedesco; Adriano Sebollela; Sebastião Sousa Almeida; José Antônio Cortes de Oliveira; Norberto Garcia-Cairasco
Journal:  Mol Neurobiol       Date:  2022-04-04       Impact factor: 5.682

6.  Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice.

Authors:  Wilma Helena Oliveira; Clarissa Figueiredo Braga; Deniele Bezerra Lós; Shyrlene Meiry Rocha Araújo; MariaEduarda Rocha França; Eduardo Duarte-Silva; Gabriel Barros Rodrigues; Sura Wanessa Santos Rocha; Christina Alves Peixoto
Journal:  Exp Brain Res       Date:  2021-07-20       Impact factor: 1.972

7.  Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl3-induced Alzheimer-like pathology model.

Authors:  Rofida A Saleh; Tarek F Eissa; Dalaal M Abdallah; Muhammed A Saad; Hanan S El-Abhar
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

8.  Targeted Metabolomic Analysis in Alzheimer's Disease Plasma and Brain Tissue in Non-Hispanic Whites.

Authors:  Karel Kalecký; Dwight C German; Albert A Montillo; Teodoro Bottiglieri
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

9.  Dementia and Adherence to Anti-Diabetic Medications: A Meta-Analysis.

Authors:  Hyder Mirghani; Samar Aljohani; Afaf Albalawi
Journal:  Cureus       Date:  2021-04-21

Review 10.  Secreted Chaperones in Neurodegeneration.

Authors:  Kriti Chaplot; Timothy S Jarvela; Iris Lindberg
Journal:  Front Aging Neurosci       Date:  2020-08-27       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.